Genomic Health, Inc. (NASDAQ:GHDX) was the recipient of a significant increase in short interest in the month of September. As of September 28th, there was short interest totalling 958,498 shares, an increase of 90.4% from the September 14th total of 503,528 shares. Based on an average trading volume of 361,338 shares, the short-interest ratio is presently 2.7 days. Approximately 2.7% of the company’s shares are short sold.

In other news, insider Steven Shak sold 5,500 shares of the company’s stock in a transaction dated Monday, September 10th. The stock was sold at an average price of $63.05, for a total value of $346,775.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO G Bradley Cole sold 5,000 shares of the company’s stock in a transaction dated Wednesday, October 10th. The stock was sold at an average price of $63.19, for a total value of $315,950.00. The disclosure for this sale can be found here. In the last three months, insiders have sold 142,529 shares of company stock valued at $8,159,120. 45.80% of the stock is owned by company insiders.

Institutional investors and hedge funds have recently modified their holdings of the stock. Globeflex Capital L P purchased a new position in Genomic Health in the second quarter valued at about $116,000. Sun Life Financial INC purchased a new position in Genomic Health in the second quarter valued at about $122,000. SG Americas Securities LLC purchased a new position in Genomic Health in the second quarter valued at about $162,000. Teacher Retirement System of Texas purchased a new position in Genomic Health in the second quarter valued at about $213,000. Finally, CAPROCK Group Inc. purchased a new position in Genomic Health in the second quarter valued at about $234,000. 89.33% of the stock is owned by hedge funds and other institutional investors.

GHDX has been the subject of several analyst reports. Zacks Investment Research raised Genomic Health from a “hold” rating to a “buy” rating and set a $67.00 target price for the company in a research report on Wednesday, August 29th. Piper Jaffray Companies upped their target price on Genomic Health from $34.00 to $50.00 and gave the stock a “neutral” rating in a research report on Friday, July 27th. Cowen reaffirmed a “hold” rating and issued a $50.00 target price on shares of Genomic Health in a research report on Monday, August 6th. Canaccord Genuity upped their target price on Genomic Health from $56.00 to $62.00 and gave the stock a “buy” rating in a research report on Friday, August 3rd. Finally, TheStreet raised Genomic Health from a “c” rating to a “b-” rating in a research report on Friday, August 3rd. Two equities research analysts have rated the stock with a sell rating, six have issued a hold rating, three have given a buy rating and one has issued a strong buy rating to the company’s stock. Genomic Health currently has an average rating of “Hold” and an average target price of $46.11.

Shares of NASDAQ GHDX opened at $65.33 on Friday. The stock has a market capitalization of $2.52 billion, a PE ratio of 6,461.00 and a beta of 0.45. Genomic Health has a 1-year low of $26.54 and a 1-year high of $72.83.

Genomic Health (NASDAQ:GHDX) last issued its quarterly earnings results on Thursday, August 2nd. The medical research company reported $0.26 EPS for the quarter, beating analysts’ consensus estimates of $0.07 by $0.19. The firm had revenue of $95.60 million during the quarter, compared to the consensus estimate of $92.23 million. Genomic Health had a return on equity of 9.09% and a net margin of 1.18%. Genomic Health’s revenue for the quarter was up 14.1% on a year-over-year basis. During the same quarter in the prior year, the business posted ($0.08) earnings per share. As a group, research analysts expect that Genomic Health will post 0.54 EPS for the current fiscal year.

About Genomic Health

Genomic Health, Inc, a healthcare company, provides actionable genomic information to personalize cancer treatment decisions worldwide. It develops and commercializes genomic-based clinical laboratory services that analyze the underlying biology of cancer, allowing physicians and patients to make individualized treatment decisions.

See Also: What is Compound Annual Growth Rate (CAGR)?

Receive News & Ratings for Genomic Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health and related companies with MarketBeat.com's FREE daily email newsletter.